Basic Information
Aeromics is a clinical-stage pharmaceutical company dedicated to developing an intravenous aquaporin-4 (AQP4) inhibitor (AER-271) for severe acute ischemic stroke, which can prevent or halt brain swelling (cerebral edema) following ischemic events.
Aeromics, Inc.
Cleveland,Ohio,United States of America
less than 15 people
January 01, 2006
info@aeromics.com